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de acção dos fármacos anabólicos e dos fármacos anti-reabsortivos e 
os estudos farmacológicos e clínicos efectuados apontam para um pro-
vável benefício para os doentes em usar ambos os agentes de forma 
complementar, isto é, iniciar o tratamento com um anabólico e segui-
damente fazer um anti-reabsortivo.
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Overt hyperthyroidism is a clinical condition caused by exagger-
ated levels of circulating thyroid hormones. Some of its main etio-
logical factors are the hyperfunction of the thyroid gland and the 
iatrogenic cause, like the ministration of excessive doses of thyroid 
hormones. Some studies have shown that the prevalence of hyper-
thyroidism in women aged 65 or more, varies between 5 and 15%. 
The potential risks of hyperthyroidism are diverse and can vary from 
patient to patient; however, heart and bone complications are rela-
tively common, especially among the elderly. Regarding the adult 
skeleton, several anomalies were described, namely reduced bone 
mineral density (BMD) and a higher osteoporotic fracture risk. In-
deed, hyperthyroidism has been recognized to be an important 
cause of secondary osteoporosis and a risk factor for hip fracture in 
women. Moreover, these osteoporotic fractures are associated with 
a risk of precocious mortality, namely in the elderly. In adult life, 
after the acquisition of the peak bone mass, the excess of circulating 
thyroid hormones can lead to an increase in bone resorption, how-
ever, the mechanisms involved in their skeletal action are far from 
totally clarified. While T3 is considered an important regulator of the 
bone tissue integrity and of the bone formation, T4 can stimulate 
directly or indirectly the activity of osteoclasts. Bone remodeling 
accelerates while the bone formation period is decreased, originat-
ing an incomplete substitution with new bone cells and loss of min-
eralized bone. It is estimated that about 10% of mineralized bone is 
loss per cycle. Furthermore, TSH is a negative regulator of bone re-
modeling, inhibiting the formation, the survival of osteoclasts and 
the differentiation of osteoblasts. Recent studies have shown that 
low TSH levels, per se, can lead to osteoporosis and fragility fractures. 
Hypercalcemia, hypercalciuria and a negative balance of calcium 
were also described. The weight loss and the gastrointestinal 
changes (decrease in intestinal calcium absorption and modified vi-
tamin D metabolism) are also associated to the reduction of the body 
lean mass, thus inducing a higher risk of fragility fractures. In old and 
young Portuguese patients with endogenous hyperthyroidism, both 
men and women, significant decreases in the BMD in several skeletal 
regions and an increase in the prevalence of osteoporosis/low BMD 
were observed. Moreover, in young Portuguese men with hyperthy-
roidism, we found a trend for an increase in the prevalence of osteo-
porotic vertebral fractures detected by VFA. In a group of 
postmenopausal women with hyperthyroidism compared to a con-
trol group, we detected a significantly higher prevalence of reduced 
BMD at all skeletal sites and also of osteoporosis. Regarding subclin-
ical hyperthyroidism in postmenopausal women, we found already 
significant correlations not only in bone turnover markers but also 
in some of the hormones implicated in bone metabolism.
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Introduction: The bone strength and fracture risk depend on sev-
eral parameters: macrogeometry of cortical bone, BMD, trabecular 
bone microarchitecture, bone microdamage, bone mineralization, 
and bone metabolism. The trabecular bone score (TBS) of the Ukrain-
ian men with osteoporotic vertebral fractures has not yet been stud-
ied.
Objectives: To evaluate TBS and BMD in men with osteoporotic 
vertebral fractures.
Methods: We’ve examined 243 men aged 30-89 years, divided 
according to the gerontologic classification: 30-44 yrs (n = 46), 45-
59 yrs (n = 83), 60-74 yrs (n = 86), 75-89 yrs (n = 28). The basic group 
consists of 52 men with osteoporotic vertebral fractures in the an-
amnesis (mean age – 59.8 ± 13.7 yrs; mean height – 1.73 ± 6.98 m; 
mean weight – 79.0 ± 14.9 kg) and control group. of 191 men without 
fractures (mean age – 57.4 ± 13.7 yrs; mean height – 1.74 ± 6.89 m; 
mean weight – 76.5 ± 9.3 kg). BMD of PA lumbar spine and proximal 
femur were measured by the DXA method (Prodigy, GEHC Lunar, 
USA) and PA spine TBS were assessed by the TBS iNsight® software 
package installed on DXA machine (Med-Imaps, Pessac, France).
Results: We have observed a significantly lower TBS in the basic 
group (30-44 yrs – 1.083 ± 0.187, 45-59 yrs – 1.025 ± 0.248, 60-74 yrs 
– 1.084 ± 0.170, 75-89 yrs – 0.951 ± 0.170) as compared to the control 
group (30-44 yrs – 1.276 ± 0.121, 45-59 yrs – 1.226 ± 0.156, 60-74 yrs 
– 1.150 ± 0.175, 75-89 yrs – 1.183 ± 0.174); F = 1.56; p < 0.001. We also 
found the lower BMD of lumbar spine in the basic group of patients 
– 30-44 yrs – 0.981 ± 0.125 g/cm2, 45-59 yrs – 1.028 ± 0.184 g/cm2, 
60-74 yrs – 1.014 ± 0.158 g/cm2, 75-89 yrs – 0.970 ± 0.183 g/cm2 
(F = 1.52; p < 0.001) and of the proximal femur – 30-44 yrs – 0.854 ± 
0.149 g/cm2, 45-59 yrs – 0.873 ± 0.139 g/cm2, 60-74 yrs – 0.823 ± 
0.136 g/cm2, 75-89 yrs – 0.716 ± 0.107 g/cm2 (F = 1.10; p < 0.001) com-
pared to the control group.
Conclusions: Subjects with vertebral fractures have TBS and BMD 
parameters significantly lower than the healthy men.
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The complications of diabetes mellitus (DM) and osteoporosis 
may cause severe morbidity and decreased longevity. Osteoporotic 
fractures are common in patients with low bone mineral density or 
with osteoporosis, but in DM the blindness and other eye problems, 
the hypertension, the cardiovascular disease, the amputations and 
other late complications such as chronic renal disease and neuropa-
thy are also common. Bone is a multifunctional tissue with mechan-
